Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A systems pharmacology model for inflammatory bowel disease.
Balbas-Martinez V, Ruiz-Cerdá L, Irurzun-Arana I, González-García I, Vermeulen A, Gómez-Mantilla JD, Trocóniz IF. Balbas-Martinez V, et al. PLoS One. 2018 Mar 7;13(3):e0192949. doi: 10.1371/journal.pone.0192949. eCollection 2018. PLoS One. 2018. PMID: 29513758 Free PMC article.
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
Kwon M, Kim G, Kim R, Kim KT, Kim ST, Smith S, Mortimer PGS, Hong JY, Loembé AB, Irurzun-Arana I, Koulai L, Kim KM, Kang WK, Dean E, Park WY, Lee J. Kwon M, et al. Among authors: irurzun arana i. J Immunother Cancer. 2022 Jul;10(7):e005041. doi: 10.1136/jitc-2022-005041. J Immunother Cancer. 2022. PMID: 35790315 Free PMC article. Clinical Trial.
Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids.
Marco-Ariño N, Vide S, Agustí M, Chen A, Jaramillo S, Irurzun-Arana I, Pacheco A, Gonzalez C, Jensen EW, Capsi-Morales P, Valencia JF, Troconiz IF, Gambus PL, Larson MD. Marco-Ariño N, et al. Among authors: irurzun arana i. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):581-593. doi: 10.1002/psp4.12729. Epub 2021 Nov 18. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34716984 Free PMC article.
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, Berges A, Cheung SYA, Irurzun-Arana I, Goldwin A, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ. Yap TA, et al. Among authors: irurzun arana i. Clin Cancer Res. 2021 Oct 1;27(19):5213-5224. doi: 10.1158/1078-0432.CCR-21-1032. Clin Cancer Res. 2021. PMID: 34301752 Free PMC article. Clinical Trial.
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J. Kim ST, et al. Among authors: irurzun arana i. Clin Cancer Res. 2021 Sep 1;27(17):4700-4709. doi: 10.1158/1078-0432.CCR-21-0251. Epub 2021 May 11. Clin Cancer Res. 2021. PMID: 33975862 Free PMC article. Clinical Trial.
13 results